Molina Medicare Advantage Drug Plans End After 2026, Leaving Thousands to Pick New Coverage by December 7
Molina Healthcare (MOH) will end its traditional Medicare Advantage drug plans by 2026, affecting about 72,000 members in California, Connecticut, and Illinois. The company recorded a $93 million impairment and expects a $1.00 per share loss from the exit, which aligns with its strategic shift. Affected members must choose new coverage by December 7 during open enrollment to avoid gaps in drug coverage.
How this was made
The 30-second read
Why it matters
The $93 million impairment and $1‑per‑share guidance reduction signal a material earnings hit, likely prompting a stock decline.
Market read
The announcement directly affects Molina's earnings outlook and may influence investor sentiment toward the broader Medicare Advantage sector.
What to watch
Potential cost savings from exiting a low‑margin product line could improve future profitability.
Background
Molina Healthcare is refocusing on dual‑eligible members, exiting its traditional Medicare Advantage drug plans.
Market effects
May pressure other Medicare Advantage insurers as the market reassesses enrollment trends.
Impacts U.S. health‑care sector, especially insurers with similar Medicare Advantage exposure.
Limited to U.S. health‑care equities.
Counterpoint
If competitors capture the displaced members, Molina could see a longer‑term market‑share gain despite short‑term hit.
Key entities
- companyMolina Healthcare
U.S. health‑care insurer (ticker MHO).
